Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial

INTRODUCTION: Infliximab (IFX), a monoclonal chimeric antibody against tumour necrosis factor (TNF) α, is effective for induction and maintenance of remission in moderate to severe Crohn's disease. Discontinuation of IFX maintenance therapy in patients in remission should be considered in order...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ Open
Hauptverfasser: Buhl, Sine Schnoor, Steenholdt, Casper, Brynskov, Jørn, Thomsen, Ole Østergaard, Bendtzen, Klaus, Ainsworth, Mark Andrew
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2014
Schlagworte:
Gastroenterology and Hepatology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4275671/
https://ncbi.nlm.nih.gov/pubmed/25524543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2014-005887
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge